ACADIA Pharmaceuticals (NASDAQ: ACAD) — Vanguard reports 0 shares in amendment
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting that it beneficially owns 0 shares of ACADIA Pharmaceuticals Inc. common stock, representing 0% of the class. The filing explains this reflects an internal realignment and the disaggregated reporting of certain Vanguard subsidiaries under SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal realignment.
The filing records 0 shares and 0% ownership as reported on the amendment; it attributes the change to an internal reorganization and disaggregated reporting by subsidiaries under SEC Release No. 34-39538.
Cash-flow treatment and any trading activity are not stated in the excerpt; subsequent filings by Vanguard subsidiaries may show holdings separately.
Amendment aligns public reporting with SEC guidance on disaggregation.
The amendment cites SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately from The Vanguard Group, Inc. This is a procedural reporting change rather than a transaction.
Stakeholders should reference future 13G/A entries from identified subsidiaries for the substantive ownership picture.